| Name | REVERSE T3 |
| Description | Reverse T3 (3,3',5'-triiodo-L-thyronine) inhibits the increase of sodium current generated by other thyroid hormone analogs in neonatal rat myocytes. |
| Cell Research | Brain death (BD) was induced in mechanically ventilated rats by inflation of a Fogarty catheter in the epidural space.?T3 (0.1 mg/kg) or vehicle was administered intraperitoneally 2 h prior to BD induction.?After 4 h of BD, serum and liver tissue were collected.?RT-qPCR, routine biochemistry, and immunohistochemistry were performed[1]. |
| In vitro | Reverse T3(T3) pre-conditioning leads to beneficial effects in the liver of brain-dead rats as seen by lower cellular injury and reduced apoptosis, and supports the suggested role of reverse T3(T3) hormone therapy in the management of brain-dead donors[1]. |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 32.55 mg/mL (50 mM)
|
| Keywords | Reverse T 3 | THR | REVERSE T-3 | REVERSE T3 | Thyroid Hormone Receptor | inhibit | Inhibitor | 3′,5′,3-Triiodothyronine |
| Inhibitors Related | Propylthiouracil | Liothyronine | L-Thyroxine | L-Thyroxine sodium | 2,2-BIS(2-HYDROXY-5-BIPHENYLYL)PROPANE | Resmetirom | Carbimazole | Liothyronine sodium | 2-Thiouracil | Tiratricol |
| Related Compound Libraries | Nuclear Receptor Compound Library | Bioactive Compound Library | Inhibitor Library | NO PAINS Compound Library | Endocrinology-Hormone Compound Library | Bioactive Compounds Library Max |
United States
